NewsRoom Articles - Page 3 of 154 - PsychedelicNewsWire (PNW)

MondayFeb 10, 2025 10:00 am

Cleveland Clinic Researchers to Test Novel Psychedelic Targeting Postpartum Depression

A team of researchers at Cleveland Clinic plans to conduct a clinical trial to test a proprietary psychedelic aimed at treating postpartum depression. This serious condition affects approximately 1 in 7 women after giving birth. The Phase 2 trial centers on RE104, a formulation that is similar to psilocybin. It is designed to be administered subcutaneously via an injection and the patient requires just one dose of this treatment. It is hoped that this treatment will address the clinical needs of new mothers afflicted by PPD and experience symptoms like sleep disturbances, chronically low mood, feelings of guilt or inadequacy,…

WednesdayFeb 05, 2025 10:00 am

Positive Clinical Trial Data Causes Psychedelic Biopharma Company’s Shares to Nearly Double

A small Ireland-based firm, GH Research, has announced positive results from a small trial it conducted to treat treatment-resistant depression. The results from this trial revealed that their inhalable version of mebufotenin was effective and fast in delivering clinically significant improvements in the patients selected for the study. Mebufotenin is molecularly similar to psilocybin and occurs in some psychedelic mushrooms. The shares of the company jumped nearly 100% upon the release of this news. The results of the trial were released on Monday, Jan. 3 and the trial involved 81 participants. The subjects all suffered from treatment-resistant depression, and evaluations…

MondayFeb 03, 2025 10:00 am

Study Finds That Psilocybin Promotes Lasting Belief Changes by Changing Neural Entropy

A new study whose findings were published in the Scientific Reports journal has revealed that psilocybin weakens the negative beliefs that an individual has and promotes well-being by ramping up neural entropy. These findings open additional possibilities for ways in which psychedelic therapy can be used in mental health care. The researchers started by tweaking the REBUS model, which says that psychedelics exert a temporal relaxation of the hierarchical organization in the brain. During this window, flexible thinking can take place. The research team made an extension to this REBUS model by introducing the REBAS model that posits that psilocybin…

WednesdayJan 29, 2025 10:00 am

Estonian Psychiatrists Advocate for the Use of Psychedelics in Treating Mental Health Conditions

Civic activists and psychiatrists in Estonia are calling for the use of psychedelics to treat various mental health conditions. An EMA (Estonian Medicines Agency) representative asserted that psychedelic research is legal in the country and caution needs to be exercised while assessing their adverse effects and therapeutic potential. Psychedelics have a long history both in their use and in scientific research. For example, many people recall the hippies of the 1960s who used LSD and also have heard about enthusiasts of electronic music that use MDMA. These uses of psychedelics invoke associations with narcotics, but that shouldn’t detract from the…

MondayJan 27, 2025 10:00 am

Massachusetts Legislators File 12 Bills Related to Psychedelics for Consideration

Last week, legislators in the state of Massachusetts filed twelve measures related to psychedelics before the filing deadline lapsed. This comes after Question 4, which would’ve decriminalized the use and possession of DMT, ibogaine, psilocybin, psilocin and mescaline and legalized therapeutic access to psychedelics for individuals aged 21 and above, was defeated at the ballot despite support from the general public. Let’s look at some of these latest measures below. Senator Cindy Friedman filed SD 1624, an act that would authorize a pilot for the use of psychedelics in licensed facilities. Under the measure, the Department of Public Health would…

WednesdayJan 22, 2025 10:00 am

UK Study to Explore DMT’s Role in Treating Alcohol Addiction

Alcohol addiction is a chronic disorder linked to the compulsive drinking of alcohol, with individuals finding it difficult to control or stop their use of alcohol despite adverse health, occupational, or social consequences. Normally, the disorder is managed with detoxes, therapy, various medications and a change in one’s lifestyle. Now researchers are looking into whether DMT can help manage the disorder. DMT is a psychedelic drug that occurs in many plants and animals, including human beings. The drug is known to affect an individual’s senses, altering how they think as well as their emotions and sense of time. The drug…

TuesdayJan 21, 2025 10:00 am

Psilocybin Triggers Personality Changes in Individuals Suffering from AUD

Patients with alcohol use disorder frequently display unusual personality traits, characterized by increased impulsivity and lack of emotional stability, alongside lower levels of cooperativeness and self-discipline. Researchers posit that these traits fuel the addiction cycle and hinder the effectiveness of treatments. Now a new study has determined that psilocybin-assisted psychotherapy can induce positive changes in the personalities of individuals with alcohol use disorder. The researchers theorized that the personality changes triggered by psilocybin-assisted psychotherapy could help individuals recovering from alcohol dependence to endure stressors that cause relapses, given the association between impulsiveness, excessive drinking, and relapses. They also cited prior…

WednesdayJan 15, 2025 10:00 am

Native American Church Decries Shortage of Psychedelic Cactus

Peyote is a variety of cactus considered to be sacred and is used in religious rites by Native Americans. The plant only grows across northern Mexico and America’s south-western region and produces mescaline, a hallucinogenic that binds to and activates certain serotonin receptors in the brain. Last week, experts warned of a peyote shortage, labeling the psychedelic renaissance occurring in the West as one of the primary causes. The West’s psychedelic renaissance began in the 50s and 60s, as more evidence surfaced of the therapeutic benefits of psychedelics like LSD and psilocybin. This saw various personalities seek out psychedelic experiences,…

MondayJan 13, 2025 10:00 am

Psychedelics Task Force in Minnesota Asks Lawmakers to Enact Legislation to Decriminalize Psychedelics

A Minnesota Psychedelic Medicine Task Force is urging legislators to create a state-regulated program for legal therapeutic access to psychedelics and decriminalize the possession and use of low amounts of psilocybin. This government task force was established through a legislation signed by Governor Tim Walz into law in May 2024. Originally, the task force was supposed to examine ketamine, mescaline, salvinorin A, ibogaine, DMT, bufotenine, 2C-B, and 5-MeO-DMT. Following the measure’s amendment, its focus shifted to LSD, psilocybin and MDMA. Its responsibilities included advising legislators on the medical, policy, and legal issues linked to the legalization of psychedelic medicine in…

MondayJan 06, 2025 10:00 am

A Recap of the Highlights for the Psychedelics Industry in 2024

The psychedelics industry experienced various peaks and pits at both the state and federal levels in 2024. Below, we look at some of the top moments of the year. Department of Veterans Affairs to fund psychedelic research for veterans Last month, the department announced that it’d allocate $1.5 million to research the effectiveness of MDMA-assisted therapy for alcohol use disorder and post-traumatic stress disorder. This psychedelic study, the first to be funded by a federal agency since the 60s, will be conducted at West Haven VA Medical Center and Providence VA Medical Center by VA researchers affiliated with Yale University…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000